Despite the paucity of data and clinical limitations, several clinical trials using preoperative low dose recombinant IFN-α [52] and IL-2 [53–56] have demonstrated less NK- and T-cell suppression and improved prognosis following surgery in patients undergoing colorectal cancer [56] and hepatic metastasis resection [57]. This evidence concerns the gene IL2 and colorectal cancer.